Stroke Clinical Trial
— "RESTORE"Official title:
REal-World Analyses of Stroke - Thrombus Occlusion REtrieval
NCT number | NCT04451525 |
Other study ID # | CL11012 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | July 15, 2020 |
Est. completion date | December 2025 |
To collect real-world evidence allowing assessment of functional, imaging, and safety outcomes of MicroVention market-released acute ischemic stroke devices when used at the direction of the treating physician.
Status | Recruiting |
Enrollment | 1000 |
Est. completion date | December 2025 |
Est. primary completion date | December 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Cohort I: Inclusion Criteria: 1. Patient is = 21 and = 85 years of age. 2. Patient has a pre-morbid mRS = 1. 3. Neuroimaging (CT/CTA and/or MR/MRA collected at no more than 90 minutes prior to groin puncture) demonstrates large vessel proximal occlusion (distal ICA through MCA bifurcation). 4. Patient has an NIHSS score = 5 at time of intervention. 5. Symptom onset is within 8 hours of when groin puncture can be achieved. 6. Patient will undergo treatment via femoral access and the decision to use femoral access has been made by the treating physician outside the context of the RESTORE study and prior to study enrollment. 7. Patient will be treated using the direct aspiration as first line treatment technique and the decision to use this technique and the study device has been made by the treating physician outside the context of the RESTORE study and prior to study enrollment. 8. Patient or patient's legally authorized representative (LAR) has provided written informed consent. 9. Patient is considered by the treating physician to be available for and able to complete all follow-up visits with a trained site investigator. Exclusion Criteria: 1. Inability to obtain written informed consent. 2. Patient is < 21 or > 85 years of age. 3. Patient has a pre-morbid mRS = 2. 4. More than 8 hours have passed since symptom onset. 5. Severe unilateral or bilateral carotid artery stenosis or dissection requiring stent treatment. 6. Presence of a pre-existing large territory infarction. 7. Absent femoral pulses or other condition preventing femoral access. 8. Patient has vascular anatomy/tortuosity or other vascular disease preventing access to the target occlusion or that will likely result in unstable access. 9. Patient is pregnant. 10. Known or suspected pre-existing/chronic large vessel occlusion in the symptomatic territory. 11. Patient has known, untreatable hypersensitivity to contrast dye, iodine or any component of the treatment device that cannot be medically controlled. 12. The intracranial occlusion is suspected to be chronic based on past imaging, clinical history, or clinical judgment. 13. Patient has a severe or life-threatening comorbidity that could confound study results, or that will render the procedure unlikely to benefit the patient. 14. Patient is unable to complete scheduled follow-up assessments due to comorbidities, geographical limitations, or a life expectancy of less than 3 months. 15. Patient is enrolled in another device or drug study in which participation could confound study results. 16. Imaging (CT or MR) exclusion criteria: - Presence of intracerebral hemorrhage as evidenced on initial imaging - Ischemic changes in the posterior circulation territories (including the vertebra-basilar and posterior cerebral arteries) - Significant mass effect with midline shift - Evidence of intracranial tumor - Baseline ischemic core lesion >50 cc - Involvement of > 1/3 of the middle cerebral artery territory - ASPECTS <6 (hemispheric sulcal effacement and/or loss of grey-white differentiation alone are not contraindications for treatment) Cohort II: Inclusion Criteria: 1. Neuroimaging (CT/CTA and/or MR/MRA) demonstrates intracranial vessel occlusion. 2. Symptom onset is within 24 hours of when arterial access puncture can be achieved. 3. Patient will be treated using an FDA-cleared/approved and market-released MicroVention mechanical thrombectomy device as the initial, primary treatment device and the decision to use this device has been made by the treating physician outside the context of the RESTORE study and prior to study enrollment. Note: For the purposes of this protocol, ancillary/accessory devices such as balloon guide catheters and other access devices are not considered primary treatment devices. Further, devices used for rescue following attempt of a different primary treatment device are not considered initial primary treatment devices. 4. Patient or patient's legally authorized representative (LAR) has provided written informed consent within 48 hours of procedure. Exclusion Criteria: 1. Inability to obtain written informed consent within 48 hours of procedure. 2. Patient is enrolled in another device or drug study in which participation could confound study results. |
Country | Name | City | State |
---|---|---|---|
United States | Augusta University | Augusta | Georgia |
United States | University of Maryland | Baltimore | Maryland |
United States | Brigham and Women's hospital | Boston | Massachusetts |
United States | SSM Health | Bridgeton | Missouri |
United States | Montefiore | Bronx | New York |
United States | Pacific Neuroscience Institute (Providence) | Burbank | California |
United States | Goodman Campbell Brain and Spine | Carmel | Indiana |
United States | Mercy San Juan - Dignity Health Research Institute | Carmichael | California |
United States | University of Cincinnati | Cincinnati | Ohio |
United States | Cleveland Clinic | Cleveland | Ohio |
United States | UCHealth Memorial | Colorado Springs | Colorado |
United States | University of Missouri | Columbia | Missouri |
United States | Geisinger | Danville | Pennsylvania |
United States | INOVA | Falls Church | Virginia |
United States | Prisma Health Upstate | Greenville | South Carolina |
United States | Memorial Healthcare System | Hollywood | Florida |
United States | Ascension Borgess | Kalamazoo | Michigan |
United States | Northshore University Hospital - Northwell | Manhasset | New York |
United States | Allina Health (Abbott Northwestern Hospital) | Minneapolis | Minnesota |
United States | HMH Jersey Shore University Medical Center | Neptune | New Jersey |
United States | University of Oklahoma Health Science Center | Oklahoma City | Oklahoma |
United States | University of Nebraska Medical Center | Omaha | Nebraska |
United States | University of Pennsylvania Health Systems | Philadelphia | Pennsylvania |
United States | Kaiser Permanente, Northern California | Redwood City | California |
United States | Javon Bea Hospital | Rockford | Illinois |
United States | Washington University | Saint Louis | Missouri |
United States | Swedish Health Services | Seattle | Washington |
United States | Sanford Medical Center | Sioux Falls | South Dakota |
United States | Baystate Medical Center | Springfield | Massachusetts |
United States | Stony Brook Medicine | Stony Brook | New York |
United States | Tampa General Hospital | Tampa | Florida |
United States | ProMedica Toledo | Toledo | Ohio |
United States | Munson Medical Center | Traverse City | Michigan |
United States | University of Michigan Health West | Wyoming | Michigan |
Lead Sponsor | Collaborator |
---|---|
Microvention-Terumo, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Cohort I: Proportion of subjects achieving mTICI = 2b revascularization based on independent core lab assessment | During the procedure | ||
Secondary | Proportion of subjects with good functional outcome defined as mRS = 2 | 90 days | ||
Secondary | Occurrence of procedure related serious adverse events | During the procedure through study completion at 90 days | ||
Secondary | Occurrence of sICH within 24 hours | 24 hours post-operative | ||
Secondary | Occurrence of embolization to new territories (ENT) | During the procedure | ||
Secondary | Presence of vasospasm involving the accessed vascular tree | During the procedure through 24 hours post-operative | ||
Secondary | Mortality at day 90 | 90 days post-procedure | ||
Secondary | Proportion of subjects achieving mTICI = 2b revascularization after first line aspiration treatment | During the procedure | ||
Secondary | Number of passes to achieve mTICI = 2b revascularization with first line aspiration treatment | During the procedure | ||
Secondary | Proportion of subjects achieving mTICI = 2b revascularization after first aspiration pass | During the procedure | ||
Secondary | Time from groin puncture to initial contact of clot with aspiration catheter | During the procedure | ||
Secondary | Time from groin puncture to achieve mTICI = 2b using first line aspiration treatment | During the procedure | ||
Secondary | Technical success using the MicroVention BOBBY Balloon Guide Catheter based on successful placement at the target location and successful balloon inflation | During the procedure |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04043052 -
Mobile Technologies and Post-stroke Depression
|
N/A | |
Recruiting |
NCT03869138 -
Alternative Therapies for Improving Physical Function in Individuals With Stroke
|
N/A | |
Completed |
NCT04034069 -
Effects of Priming Intermittent Theta Burst Stimulation on Upper Limb Motor Recovery After Stroke: A Randomized Controlled Trial
|
N/A | |
Completed |
NCT04101695 -
Hemodynamic Response of Anodal Transcranial Direct Current Stimulation Over the Cerebellar Hemisphere in Healthy Subjects
|
N/A | |
Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
Completed |
NCT00391378 -
Cerebral Lesions and Outcome After Cardiac Surgery (CLOCS)
|
N/A | |
Recruiting |
NCT06204744 -
Home-based Arm and Hand Exercise Program for Stroke: A Multisite Trial
|
N/A | |
Active, not recruiting |
NCT06043167 -
Clinimetric Application of FOUR Scale as in Treatment and Rehabilitation of Patients With Acute Cerebral Injury
|
||
Active, not recruiting |
NCT04535479 -
Dry Needling for Spasticity in Stroke
|
N/A | |
Completed |
NCT03985761 -
Utilizing Gaming Mechanics to Optimize Telerehabilitation Adherence in Persons With Stroke
|
N/A | |
Recruiting |
NCT00859885 -
International PFO Consortium
|
N/A | |
Recruiting |
NCT06034119 -
Effects of Voluntary Adjustments During Walking in Participants Post-stroke
|
N/A | |
Completed |
NCT03622411 -
Tablet-based Aphasia Therapy in the Chronic Phase
|
N/A | |
Completed |
NCT01662960 -
Visual Feedback Therapy for Treating Individuals With Hemiparesis Following Stroke
|
N/A | |
Recruiting |
NCT05854485 -
Robot-Aided Assessment and Rehabilitation of Upper Extremity Function After Stroke
|
N/A | |
Active, not recruiting |
NCT05520528 -
Impact of Group Participation on Adults With Aphasia
|
N/A | |
Completed |
NCT03366129 -
Blood-Brain Barrier Disruption in People With White Matter Hyperintensities Who Have Had a Stroke
|
||
Completed |
NCT03281590 -
Stroke and Cerebrovascular Diseases Registry
|
||
Completed |
NCT05805748 -
Serious Game Therapy in Neglect Patients
|
N/A | |
Recruiting |
NCT05621980 -
Finger Movement Training After Stroke
|
N/A |